Cargando…

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround tim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makimoto, Go, Shimonishi, Atsushi, Ohashi, Kadoaki, Ninomiya, Kiichiro, Higo, Hisao, Kato, Yuka, Fujii, Masanori, Kubo, Toshio, Ichihara, Eiki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149432/ https://www.ncbi.nlm.nih.gov/pubmed/35702678 http://dx.doi.org/10.1159/000524326

Ejemplares similares

Massive hemoptysis in a post-operative patient with recurrent lung cancer successfully treated by the combination therapy of Endobronchial Watanabe Spigot and bronchial artery embolization
por: Taoka, Masataka, et al.
Publicado: (2022)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression
por: Nishii, Kazuya, et al.
Publicado: (2021)

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
por: Ichihara, Eiki, et al.
Publicado: (2018)

Combined effect of cabozantinib and gefitinib in crizotinib‐resistant lung tumors harboring ROS1 fusions
por: Kato, Yuka, et al.
Publicado: (2018)

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
por: Kudo, Kenichiro, et al.
Publicado: (2017)

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019)

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
por: Okawa, Sachi, et al.
Publicado: (2021)

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers
por: Watanabe, Hiromi, et al.
Publicado: (2021)

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
por: Morichika, Daisuke, et al.
Publicado: (2016)

Identification of targetable kinases in idiopathic pulmonary fibrosis
por: Higo, Hisao, et al.
Publicado: (2022)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Hara, Naofumi, et al.
Publicado: (2023)

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages
por: Watanabe, Hiromi, et al.
Publicado: (2019)

Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan
por: Ando, Eri, et al.
Publicado: (2021)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
por: Watanabe, Hiromi, et al.
Publicado: (2017)

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2011)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
por: Takamori, Shinkichi, et al.
Publicado: (2021)

Treatment-Related Death in Patients with Small-Cell Lung Cancer in Phase III Trials over the Last Two Decades
por: Ochi, Nobuaki, et al.
Publicado: (2012)

Managing Lung Cancer with Comorbid Interstitial Pneumonia
por: Ichihara, Eiki, et al.
Publicado: (2019)

Utility of immune checkpoint inhibitors in non‐small‐cell lung cancer patients with poor performance status
por: Kano, Hirohisa, et al.
Publicado: (2020)

Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
por: Błaszkowska, M., et al.
Publicado: (2022)

Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography
por: Minami, Daisuke, et al.
Publicado: (2016)

Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2015)

Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation: Case Report
por: Hashiguchi, Mizuha Haraguchi, et al.
Publicado: (2021)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping
por: Yang, Mo, et al.
Publicado: (2023)

Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
por: Veillon, Remi, et al.
Publicado: (2022)

Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report
por: Tseng, Liang-Wei, et al.
Publicado: (2022)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results
por: Oze, Isao, et al.
Publicado: (2009)

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report
por: Ninomaru, Taira, et al.
Publicado: (2021)

Long-term spontaneous remission with active surveillance in IgG4-related pleuritis: A case report and literature review
por: Makimoto, Go, et al.
Publicado: (2019)

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
por: Inno, Alessandro, et al.
Publicado: (2023)

Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?
por: Sato, Hiroki, et al.
Publicado: (2018)

The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study
por: Nishimura, Tomoka, et al.
Publicado: (2022)

TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION
por: Bestvina, Christine M, et al.
Publicado: (2021)

SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION
por: Leighl, Natasha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7la8ingsarfko0r3iusgeiumlu